Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: A randomized crossover study

American Journal of Kidney Diseases

Volumn 65, Issue 6, 2015, Pages 916-924

  Jeong, Kyung Hwan ^a   Cho, Ju Hee ^a   Woo, Jong Shin ^a   Kim, Jin Bae ^a   Kim, Woo Shik ^a   Lee, Tae Won ^a   Kim, Kwon Sam ^a   Ihm, Chun Gyoo ^a   Kim, Weon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

antiplatelet therapy; clopidogrel; end stage renal disease (ESRD); hemodialysis (HD); high on treatment platelet reactivity (HTPR); kidney failure; platelet aggregation assay; Platelet inhibition; platelet reactivity; thrombosis; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ABNORMAL LABORATORY RESULT; ADULT; ALLELE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GENOTYPE; HEARING DISORDER; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; ORAL BLEEDING; PATIENT COMPLIANCE; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG COMBINATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SINGLE BLIND PROCEDURE; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT OUTCOME;

ADENOSINE; ADULT; ASPIRIN; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RENAL DIALYSIS; SINGLE-BLIND METHOD; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84930439420     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.11.023     Document Type: Article

References (25)

1. P.J. Best, S.R. Steinhubl, and P.B. Berger The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 155 4 2008 687 693
2. N.D. Lambert, M.T. Sacrinty, and T.R. Ketch Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction Am Heart J 157 4 2009 688 694
3. Z.B. Zhu, R.Y. Zhang, and Q. Zhang Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT Study Cardiology 112 3 2009 191 199
4. J.S. Woo, W. Kim, and S.R. Lee Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease (PIANO-2 CKD) randomized study Am Heart J 162 6 2011 1018 1025
5. S.H. Park, W. Kim, C.S. Park, W.Y. Kang, and S.H. Hwang A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure Am J Cardiol 104 9 2009 1292 1295
6. O. Morel, S. El Ghannudi, and L. Jesel Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel J Am Coll Cardiol 57 4 2011 399 408
7. G.W. Stone, B. Witzenbichler, and G. Weisz Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 9892 2013 614 623
8. J.W. Suh, S.P. Lee, and K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 3 2011 280 289
9. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 25 2009 2577 2585
10. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 18 2010 1456 1462
11. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
12. S. James, A. Budaj, and P. Aylward Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 122 11 2010 1056 1067
13. D. Alexopoulos, A. Galati, and I. Xanthopoulou Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 3 2012 193 199
14. D. Alexopoulos, I. Xanthopoulou, T.E. Plakomyti, P. Goudas, E. Koutroulia, and D. Goumenos Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis Am J Kidney Dis 60 2 2012 332 333
15. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 13 2004 1296 1305
16. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 8 2008 992 1000
17. J. Borlak, and T. Thum Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis Clin Chem 48 9 2002 1592 1594
18. M.J. Price, J.L. Coleman, S.R. Steinhubl, G.B. Wong, C.P. Cannon, and P.S. Teirstein Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers Am J Cardiol 98 5 2006 681 684
19. D. Alexopoulos, A. Panagiotou, and I. Xanthopoulou Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity J Thromb Haemost 9 12 2011 2379 2385
20. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 23 2003 2908 2913
21. J.S. Woo, W. Kim, H.H. Jang, J.B. Kim, W.S. Kim, and K.S. Kim Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy Am J Cardiol 113 5 2014 786 792
22. D.J. Angiolillo, E. Bernardo, and D. Capodanno Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J Am Coll Cardiol 55 11 2010 1139 1146
23. A. Aggarwal, S.S. Kabbani, and J.M. Rimmer Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk Am J Kidney Dis 40 2 2002 315 322
24. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 16 2010 1821 1830
25. K. Butler, and R. Teng Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment J Clin Pharmacol 52 9 2012 1388 1398